Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN20 in Primary Immune Thrombocytopenia (ITP)
NCT06880081Phase 1Completed
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PJ004 in primary immune thrombocytopenia (ITP), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. Primary endpoint: Adverse Events at 28 days. Started Mar 2025; status: completed.
02
Drugs
PJ004
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06880081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06880081.